Impact of treatment delay in acute myeloid leukemia revisited
Blood Adv
.
2021 Feb 9;5(3):787-790.
doi: 10.1182/bloodadvances.2020003806.
Authors
Gunnar Juliusson
1
2
3
4
,
Oskar Hagberg
5
,
Vladimir Lj Lazarevic
1
,
Sören Lehmann
6
7
,
Martin Höglund
6
7
Affiliations
1
Department of Hematology, Skåne University Hospital, Lund, Sweden.
2
Department of Hematology.
3
Stem Cell Center.
4
Department of Laboratory Medicine, and.
5
Department of Cancer Epidemiology, Lund University, Lund, Sweden.
6
Department of Medical Sciences, Uppsala University, Uppsala, Sweden; and.
7
Division of Hematology, Uppsala University Hospital, Uppsala, Sweden.
PMID:
33560387
PMCID:
PMC7876876
DOI:
10.1182/bloodadvances.2020003806
No abstract available
Publication types
Research Support, Non-U.S. Gov't
MeSH terms
Humans
Leukemia, Myeloid, Acute* / drug therapy
Mutation
Time-to-Treatment*